TSHA Taysha Gene Therapies, Inc.
Healthcare$5.49-0.90%ClosedMarket Cap: $1.37B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
9.50
P/S
183.88
EV/EBITDA
-8.56
DCF Value
$0.64
FCF Yield
-8.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-1774.4%
Net Margin
-1738.4%
ROE
-56.1%
ROA
-43.2%
ROIC
-47.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-43.5M | $-42.4M | $— | — |
| Q4 null | $5.5M | 94.5% | $-28.3M | $-27.9M | $— | — |
| FY null | $9.8M | 100.0% | $-110.5M | $-109.0M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-34.0M | $-32.7M | $— | — |
| Q2 null | $2.0M | 100.0% | $-26.8M | $-26.9M | $— | — |
| Q1 null | $2.3M | 100.0% | $-21.4M | $-21.5M | $— | — |
| Q4 null | $2.0M | 100.0% | $-19.9M | $-18.8M | $— | — |
| FY null | $8.3M | 100.0% | $-91.5M | $-89.3M | $— | — |
| Q3 null | $1.8M | 100.0% | $-25.9M | $-25.5M | $— | — |
| Q2 null | $1.1M | 100.0% | $-21.3M | $-20.9M | $— | — |
| Q1 null | $3.4M | 100.0% | $-24.3M | $-24.1M | $— | — |
| Q4 2023 | $3.6M | 100.0% | $-16.2M | $47.7M | $0.26 | — |